Synthesis of β-phthalimido-alcohols via regioselective ring opening of epoxide by using reusable basic magnetic nano particles and their biological investigation

Mohammad Ali Zolfigol*a, Ahmad Reza Moosavi-Zare*b, Mahmoud Zareia, Abdolkarim Zarec, Ehsan Noroozizadeha, Roya Karamiand and Mostafa Asadbegyd
aDepartment of Organic Chemistry, Faculty of Chemistry, Bu-Ali Sina University, Hamedan 6517838683, Iran. E-mail: zolfi@basu.ac.ir; mzolfigol@yahoo.com; Fax: +98 8138380709; Tel: +98 8138282807
bSayyed Jamaleddin Asadabadi University, Asadabad, 6541835583, Iran. E-mail: moosavizare@yahoo.com
cDepartment of Chemistry, Payame Noor University, Iran
dDepartment of Biology, Faculty of Science, Bu-Ali Sina University, Hamedan, 65175/4161, Iran. E-mail: R_karamian@basu.ac.ir

Received 23rd March 2016 , Accepted 17th June 2016

First published on 17th June 2016


Abstract

In this work, tetra butyl ammonium hydroxide ([Bu4N]OH) and magnetic nano particles (Fe3O4@SiO2@(CH2)3NH2) were introduced as efficient catalysts for the regioselective ring opening of epoxides including aromatic and aliphatic of epoxides to give the corresponding β-phthalimido-alcohols under mild conditions. A various range of β-phthalimido-alcohols as new compounds were prepared and fully characterized by IR, 1H as well as 13C NMR and mass spectra. Also the synthesized compounds were studied for antioxidant properties by DPPH free radical scavenging assay. The results indicated that studied β-phthalimido-alcohols derivatives have effective antioxidant functions (IC50: 0.142–0.356 mg mL−1) in compare with BHT (IC50: 0.122 mg mL−1) and ascorbic acid (IC50: 0.146 mg mL−1) as standards. This may be a new health-care food and drug supplement for special use in the future.


Introduction

Epoxides are important starting materials and useful synthetic intermediates in organic synthesis. Also, the conversion of an alkene to an epoxide is a part of a more extensive molecular transformation.1 Since epoxide ring opening is usually stereospecific, such reactions can be used to establish stereochemical relationships between adjacent substituents.2 For this purpose, a wide range of mono or 1,2-disubstituted products, have been synthesized via addition of various nucleophiles to epoxides and different promoters and conditions have been proposed.3 Ring opening of epoxides have been carried out with various nucleophiles such as phenols1,4,5 thiols and thiophenols,5,11 indoles,6,11 amines,7 sulfonamides,8 thiocyanate,9 azide,10 benzotriazole,11 alcohols,11,12 AcOH,12 H2O,12 cyanide,10e,13 sulfide14 and a good range of anions.15 Almost, the above mentioned ring opening of epoxides have been carried out by applying acids or bases as catalysts in the course of reactions so that literature surveys shows that there are a few reports for ring opening of epoxides under neutral conditions.16

Phthalimide is a very important starting synthone in organic synthetic methodology for preparing diverse functionalized molecules.17 The most famous and oldest applications of phthalimide is Gabriel synthesis for converting halides to aliphatic and aromatic amines. Nowadays, it has been used for the synthesis of catalysts,18 complicated19 and advanced materials.20 Moreover, phthalimide and its analogues have been extensively used in medicinal chemistry owing to their wide range of applications for designing of diverse biologically active molecules such as anti-convulsant, anti-inflammatory, analgesic, hypolipidemic, immunomodulatory activities, antitumor drugs21 and anti HIV.22 Free radicals such as reactive oxygen species (ROS) are formed naturally in the body with important roles in cell signaling, however some environmental toxins may contain free radicals or stimulate the body's cells to produce free radicals.23 High level of free radicals are hazardous to the body and damage all major components of cells, including nucleic acids, proteins and plasma membrane, may play a role in the development of cancer and other health conditions.24 A present trend in the field of antioxidant development focuses on multipotent antioxidant agents that can prevent biological substrates from radical induced oxidative damage.25 Antioxidants may act as free radical scavengers, reducing agents, quenchers of singlet oxygen molecules and/or activators of antioxidative defense enzyme systems to suppress the radical damages in biological systems.26,27 Antioxidant agents such as butylated hydroxyanisole (BHA) and butylated hydroxytoluene (BHT) are applied as additives in foods to prevent oxidation of lipids. Also, BHA and BHT are restricted by legislative rules because of doubts over their toxic and carcinogenic effects.28 Therefore, there is a growing request and interest for safer antioxidants in food and pharmaceutical applications.29 Recently, phthalimide and its salts including potassium phthalimide has been also widely used as catalyst in organic synthetic chemistry.30 Therefore, development of eco-friendly protocols using more efficient, recycle and reusable nano magnetic catalysts31 for regioselective aminolysis of epoxides under green conditions is in more demand.32 In continuation of our previous studies on the synthesis of nano magnetic catalysts33 and development of task specific ionic liquids (TSILs),34 nucleophilic ability of phthalimide,35 and ring opening of epoxides,36 we found that desirable structural diversity of functionalized phthalimides could be achieved via joining all of these research areas to design a new reaction procedure for the synthesis of β-phthalimido-alcohols under solvent-free conditions (Scheme 1). Also results indicated that β-phthalimido-alcohols derivatives studied have remarkable antioxidant functions.


image file: c6ra07660b-s1.tif
Scheme 1 The reaction of phthalimide with epoxide catalyzed by Fe3O4@SiO2@(CH2)3NH2 or [Bu4N]OH.

Development of task specific catalysts and their structural diversity could be achieved via a combination of the desired structural moiety or functional group within a catalyst core. On the other hand, development of task specific ionic liquids (TSILs) and their structural diversity could be achieved via designing and synthesis of novel cationic cores with suitable anionic counterparts. By considering the above mentioned synthetic strategy, in the course of our investigation we decided to use tetra butyl ammonium hydroxide ([Bu4N]OH) as a commercially available IL and Fe3O4@SiO2@(CH2)3NH2 as basic magnetic nano particles for the ring opening of epoxides with phthalimide under solvent free-conditions (Scheme 1).

At first, the SEM micrographs of prepared Fe3O4@SiO2@(CH2)3NH2 as basic magnetic catalyst was investigated to show that the particles were obtained in nano size (Fig. 1).


image file: c6ra07660b-f1.tif
Fig. 1 SEM micrographs of Fe3O4@SiO2@(CH2)3NH2.

Then, as a model reaction, the condensation of phthalimide (1) (1 mmol) with 2-phenyl oxirane (1 mmol) was selected in the presence of different amounts of the tetra butyl ammonium hydroxide, at range of 80–110 °C under solvent-free conditions. The results are summarized in Table 1. As it is shown at Table 1, indicates that 15 mol% of [Bu4N]OH was sufficient to afford the desired product in excellent yield and in very short reaction time at 110 °C (Table 1, entry 2). No improvement in the reaction results was observed by increasing the amount of the catalyst and the temperature. The solvent-free condensation was also tested at 110 °C without catalyst in which the reaction was not progressed even after long reaction time (2 h). Also, the solvent-free reaction of phthalimide with 2-phenyl oxirane was tested using Fe3O4@SiO2@(CH2)3NH2 at 110 °C. The best result was given by 1 mg of catalyst after 15 minutes (Table 1, entry 7).

Table 1 Effect of different amounts of the catalysts and temperature on the reaction between phthalimide with 2-phenyl oxirane
Catalyst Amount of catalyst Temp. (°C) Time (min) Yielda (%)
a Isolated yield.
[Bu4N]OH 5 mol% 80 40 60
[Bu4N]OH 15 mol% 110 22 91
[Bu4N]OH 10 mol% 110 35 65
[Bu4N]OH 20 mol% 110 21 91
[Bu4N]OH 15 mol% 90 30 57
Fe3O4@SiO2@(CH2)3NH2 0.5 mg 80 17 70
Fe3O4@SiO2@(CH2)3NH2 1 mg 110 17 94
Fe3O4@SiO2@(CH2)3NH2 3 mg 110 15 94
Fe3O4@SiO2@(CH2)3NH2 0.5 mg 110 35 52
Fe3O4@SiO2@(CH2)3NH2 1 mg 90 25 65


The condensation of phthalimide (1) (1 mmol) with 2-phenyl oxirane (1 mmol), as model reaction, was examined by some various organic and inorganic bases such as LiOH, KOH, NaOH, NaCO3, DABCO and Et3N to choose the best basic catalyst (Table 2). As Table 2 indicates that ([Bu4N]OH) and Fe3O4@SiO2@(CH2)3NH2 are more successful than other bases.

Table 2 Evaluation of various bases on the reaction between phthalimide with 2-phenyl oxirane in comparison with Fe3O4@SiO2@(CH2)3NH2 and [Bu4N]OH
Base Amount of catalyst (mol%) Temp. (°C) Time (min) Yielda (%)
a Isolated yield.
LiOH 15 120 110 0
KOH 15 120 110 20
NaOH 15 120 110 30
DABCO 15 120 110 35
Et3N 15 120 110 30
[Bu4N]OH 15 110 22 91
Fe3O4@SiO2@(CH2)3NH2 1 mg 110 17 94


To compare the efficiency of solution conditions versus the solvent-free conditions, a mixture of phthalimide (1 mmol) and 2-phenyl oxirane (1 mmol) in the presence of [Bu4N]OH was heated in an oil-bath (110 °C) in various solvents for 60 min. Low yields of the product was obtained, even after elongated reaction times (Table 3). In the solvent-free conditions, the starting materials (phthalimide and 2-phenyl oxirane) and the catalyst formed a homogeneous system in the reaction media. This homogeneous system was also examined using various solvents including CHCl3, EtOH, EtOAC, CH2Cl2 and H2O. Therefore, the catalytic activity of [Bu4N]OH decreased in the presence of these solvents. In the case of H2O as solvent, [Bu4N]OH was soluble in water, but the starting materials were insoluble in it. Then, the yield decreased when H2O was applied as solvent. Therefore, the solvent-free reaction was more efficient than solution conditions.

Table 3 The effect of various solvents on the reaction of phthalimide (1 mmol) with 2-phenyl oxirane (1 mmol) by method A and B in comparison with solvent-free conditions
Solvent Temperature Time (min) Yielda (%) A/Bb
a Isolated yield.b In method A, [Bu4N]OH was used as basic catalyst and in method B, Fe3O4@SiO2@(CH2)3NH2 was used.
EtOAc Reflux 60 45/40
CHCl3 Reflux 60 55/33
EtOH Reflux 60 40/54
CH2Cl2 Reflux 60 50/35
H2O r.t. 120 0/0
H2O Reflux 120 20/25
110 °C 22/17 91/94


In order to assess the scope and the generality of the catalysts, the condensation of phthalimide with various epoxides was tested in the presence of 15 mol% [Bu4N]OH at 110 °C in the absence of solvent. The results are depicted in Table 4. As it is shown in Table 4, epoxide rings were utilized successfully in the reaction, and gave the desired products in high yields and in very short reaction times. Thus, the catalyst was general and highly efficient. Interestingly, the condensation of phthalimide (2 eq.) with 2-(4-(oxiran-2-yl)butyl)oxirane (1 eq.) in the presence of [Bu4N]OH (30 mol%) at 110 °C under solvent-free conditions, afforded (2,2′-(2,7-dihydroxyoctane-1,8-diyl)diisoindoline-1,3-dione) in 90% of yield within 25 minutes (Scheme 2).

Table 4 The preparation of β-phthalimido-alcohols using method A/Ba
Product Time (min) Yieldb (%) Mp °C
a In method A, [Bu4N]OH was used as basic catalyst and in method B, Fe3O4@SiO2@(CH2)3NH2 was used as basic catalyst.b Isolated yield.c These epoxides were used 3 mmol against of 1 mmol of phthalimide.d These products were purified by plate chromatography.
image file: c6ra07660b-u1.tif 35/30 85/85c 103–105
image file: c6ra07660b-u2.tif 22/19 88/90 104–106
image file: c6ra07660b-u3.tif 22/17 91/94 159–161
image file: c6ra07660b-u4.tif 32/25 80/82c 234–238
image file: c6ra07660b-u5.tif 25/21 87/90 203–205
image file: c6ra07660b-u6.tif 45/40 81/84d 173–176
image file: c6ra07660b-u7.tif 25/21 72/76d 132–135
image file: c6ra07660b-u8.tif 30/23 80/85 125–128
image file: c6ra07660b-u9.tif 35/28 86/92 121–123
image file: c6ra07660b-u10.tif 29/21 83/89 109–112



image file: c6ra07660b-s2.tif
Scheme 2 The condensation of phthalimide with 2-(4-(oxiran-2-yl)butyl)oxirane.

In a plausible mechanism (Scheme 3), at first, phthalimide, as an acid, reacted with Fe3O4@SiO2@(CH2)3NH2 as a basic catalyst. The produced phthalimide anion attacked to the epoxide and opened it. Then, (I), as an anion, reacted with Fe3O4@SiO2@(CH2)3NH3+ to give the desired product and the basic catalyst. The produced catalyst utilized the reaction to complete it.


image file: c6ra07660b-s3.tif
Scheme 3 The plausible mechanism for the synthesis of β-phthalimido-alcohols.

The model reaction was also studied using potassium phthalimide instead of phthalimide in this reaction condition. The reaction was not carried out due to the absence of acidic hydrogen in phthalimide anion. The ring of epoxide could be opened by phthalimide anion, but in a reversible reaction the epoxide and phthalimide anion were prepared again. This observation clearly confirmed the mechanism of the reaction.

In another study, reusability of the catalyst was tested upon the reaction of phthalimide (1 mmol) with phenyl oxirane (1 mmol). The reaction mixture was extracted by warm ethanol to separate from the catalyst. Afterward, the reused catalyst was used for another reaction. We observed that the catalytic activity of the catalyst was restored within the limits of the experimental errors for four successive runs.

Antioxidant activity

Antioxidant properties, especially radical scavenging activities, are very important due to the deleterious role of free radicals in foods and biological systems.37 Free radical scavenging activity of the synthesized compounds (C1–C9) assayed by 2,2-diphenyl-1-picrylhydrazyl radical (DPPH) and comparison with ascorbic acid and BHT as a standard. Assessment of antioxidant activity showed that all compounds have effective free radical scavenging activity but in average function, compounds not showed different remarkable in amount of scavenging activity (62.92–73.71%) (Table 5). The higher antioxidant activity is reflected in a lower IC50 value (mg mL−1). The effectiveness of antioxidants as DPPH radical scavengers ranged based on the IC50 value in the following descending order: BHT > C3 = C6 ≥ ascorbic acid ≥ C2C7C1 > C5C8 > C9 > C4 (Table 5). The above results indicate that the synthesized compounds may be used in the treatment of diseases caused by free radicals. Further studies are needed to evaluate the in vivo potential of these compounds in animal models.
Table 5 Comparison of DPPH radical scavenging activity of β-phthalimido-alcohols derivatives and ascorbic acid as a standarda
Compounds Concentration (mg mL−1)
0.2 0.4 0.6 0.8 1 Average IC50
a Experiment was performed in triplicate and expressed as mean ± SD. Values along column with different superscripts are significantly different (p < 0.05).
1 59.16 ± 2.7a 67.35 ± 1.5b 66.26 ± 1.3b 68.18 ± 2.6b 71.14 ± 3.3b 66.42 0.169cd
2 65.21 ± 2.1a 66.55 ± 2.2a 64.23 ± 2.4a 69.17 ± 1.2b 69.46 ± 1.6b 66.92 0.153c
3 70.56 ± 3.3a 71.23 ± 2.3a 70.00 ± 2.5a 75.13 ± 1.1b 78.32 ± 2.4b 73.05 0.142b
4 48.33 ± 1.8a 56.14 ± 1.2b 67.35 ± 2.4c 69.17 ± 2.2c 73.61 ± 1.5c 62.92 0.356f
5 55.45 ± 2.6a 67.45 ± 2.7b 72.25 ± 1.2c 78.26 ± 3.2c 81.51 ± 1.3d 71.02 0.180d
6 70.24 ± 1.3a 71.27 ± 2.1a 75.16 ± 1.8a 73.24 ± 2.6a 78.65 ± 3.3b 73.71 0.142b
7 61.56 ± 2.8a 65.23 ± 1.9a 73.54 ± 2.7b 76.34 ± 3.2b 76.43 ± 2.5b 71.22 0.162c
8 55.32 ± 3.1a 62.15 ± 2.7b 64.15 ± 3.1b 64.58 ± 2.6b 68.21 ± 2.4b 62.88 0.181d
9 50.62 ± 1.2a 53.21 ± 1.6a 61.41 ± 2.3b 69.74 ± 2.5c 76.25 ± 1.1d 62.25 0.197e
10 58.21 ± 2.2a 57.36 ± 3.1a 58.41 ± 1.9a 64.21 ± 1.4b 69.33 ± 2.6b 61.50 0.172d
Ascorbic acid 68.74 ± 2.7a 76.16 ± 3.4b 78.85 ± 1.4b 80.41 ± 2.2b 80.24 ± 1.6b 76.88 0.146b
BHT 82.24 ± 0.8a 87.65 ± 1.1b 89.26 ± 1.6b 88.12 ± 2.7b 92.37 ± 1.4b 76.88 0.122a


DPPH radical scavenging assay

The free radical scavenging activity of the compounds synthesized in this studied were evaluated using the stable radical DPPH.39 Briefly, 0.3 mM DMSO solution of DPPH (1 mL) was added to samples (2.5 mL) containing different synthesized compounds. The samples were first kept in a dark place at room temperature and their absorbance was read at 517 nm after 30 min. The antioxidant activity (AA) was determined using the following formula:
AA% = 1 − [(As − Ab)/Ac] × 100

Blank samples contained 1 mL DMSO + 2.5 mL from various concentrations of synthesized compounds; control sample containing 1 mL of 0.3 mM DPPH + 2.5 mL DMSO. The optic density of the samples, the control and the empty samples were measured in comparison with DMSO. Two synthetic antioxidant, ascorbic acid and BHT were used as standards. The discoloration was plotted against the sample concentration in order to calculate the IC50 value, which is the amount of sample necessary to decrease the absorbance of DPPH by 50%. Experiments were carried out triplicate.

Statistical analysis

Data obtained from antioxidant assay is the average of triplicate analyses and recorded as mean ± standard deviation. Analysis of variance was performed by Excel procedures statistical analysis was performed using student's t-test, and p value < 0.05 was regarded as significant.

Conclusions

In summary, we have introduced tetrabutyl ammonium hydroxide [Bu4N]OH, as homogeneous catalyst, for the synthesis of β-phthalimido-alcohols under green media. Also, basic magnetic nano particles, (Fe3O4@SiO2@(CH2)3NH2), as heterogeneous catalyst, was employed in this transformation. The promising points for the presented methodology are efficiency, generality, high yield, relatively short reaction time, low cost, cleaner reaction profile, ease work-up and finally compliance with the green chemistry protocols. Results from present study clearly demonstrated that all β-phthalimido-alcohols derivatives exhibit antioxidant properties that might be helpful in preventing the progress of various diseases and development of novel therapeutic agents. Of course, other effects of newly synthesized compounds in this research must be studied under in vivo condition.

Experimental

All chemicals were purchased from Merck or Fluke Chemical Companies. Magnetic nanoparticles were prepared according the previous literature.38 Progress of the reactions was monitored by TLC using silica gel SIL G/UV 254 plates. The 1H NMR (400 or 300 MHz) and 13C NMR (100 or 75 MHz) were run on a Bruker Avance DPX-250 FT-NMR spectrometer (δ in ppm). Microanalyses were performed on Perkin-Elmer 240-B microanalyses. Melting points were recorded on a Büchi B-545 apparatus in open capillary tubes.

General procedure for the synthesis of β-phthalimido-alcohols using [Bu4N]OH

A mixture of phthalimide (0.147 g, 1 mmol), epoxide (1 mmol), and [Bu4N]OH (0.15 mol%) in a 10 mL round-bottomed flask, connected to a reflux condenser, was stirred in an oil-bath at 110 °C. After completion of the reaction, as monitored by TLC, the reaction mixture was cooled to room temperature, extracted with CHCl3 (10 mL) and H2O (10 mL) to separate the catalyst. The product was recrystallized in CHCl3 to afford the pure product, which required no further purification.

General procedure for the synthesis of β-phthalimido-alcohols using nano Fe3O4@NH2

A mixture of phthalimide (0.147 g, 1 mmol), epoxide (1 mmol), and nano Fe3O4@SiO2@(CH2)3NH2 (1 mg) in a 10 mL round-bottomed flask connected to a reflux condenser, was stirred in an oil-bath (110 °C). After completion of the reaction, as monitored by TLC, the reaction mixture was cooled to room temperature, extracted with ethanol separate the catalyst. The product was recrystallized in ethanol to afford the pure product which required no further purification.

Acknowledgements

We thank Bu-Ali Sina University and Iran National Science Foundation (INSF) (The Grant of Allameh Tabataba'i's Award, Grant Number BN093) for financial support to our research group.

Notes and references

  1. H. Lu, J. Zhou, H. Cheng, L. Sun, F. Yang, R. Wu, Y. Gao and Z. Luo, Tetrahedron, 2013, 69, 11174–11184 CrossRef CAS.
  2. I. M. Pastor and M. Yus, Curr. Org. Chem., 2005, 9, 1–29 CrossRef CAS.
  3. S. Bonollo, D. Lanari and L. Vaccaro, Eur. J. Org. Chem., 2011, 14, 2587–2598 CrossRef.
  4. J. M. Ready and E. N. Jacobsen, J. Am. Chem. Soc., 1999, 121, 6086–6087 CrossRef CAS.
  5. (a) A. Z. Halimehjani, A. Jalali, M. Khalesi, A. Ashouri and K. Marjani, Synth. Commun., 2011, 41, 1638–1643 CrossRef CAS; (b) H. Firouzabadi, N. Iranpoor, A. A. Jafari and S. Makarem, J. Mol. Catal. A: Chem., 2006, 250, 237–242 CrossRef CAS.
  6. (a) M. L. Kantam, S. Laha, J. Yadav and B. Sreedhar, Tetrahedron Lett., 2006, 47, 6213–6216 CrossRef CAS; (b) K. Tabatabaeian, M. Mamaghani, N. O. Mahmoodi and A. Khorshidi, Tetrahedron Lett., 2008, 49, 1450–1454 CrossRef CAS.
  7. (a) A. K. Shah, K. J. Prathap, M. Kumar, S. H. R. Abdi, R. I. Kureshy, N. H. Khan and H. C. Bajaj, Appl. Catal., A, 2014, 469, 442–450 CrossRef CAS; (b) C. Thomas, S. Brut and B. Bibal, Tetrahedron, 2014, 70, 1646–1650 CrossRef CAS; (c) L. C. D. Rezende, F. Fumagalli, M. S. Bortolin, M. G. Oliveira, M. H. Paula, V. F. Andrade-Neto and F. S. Emery, Bioorg. Med. Chem. Lett., 2013, 23, 4583–4586 CrossRef CAS PubMed; (d) S. P. Pathare and K. G. Akamanchi, Tetrahedron Lett., 2013, 54, 6455–6459 CrossRef CAS; (e) A. Ziyaei-Halimehjani, H. Gholami and M. R. Saidi, J. Iran. Chem. Soc., 2013, 10, 7–11 CrossRef CAS; (f) N. Tan, S. Yin, Y. Li, R. Qiu, Z. Meng, X. Song, S. Luo, C.-T. Au and W.-Y. Wong, J. Organomet. Chem., 2011, 696, 1579–1583 CrossRef CAS; (g) N. Azizi and M. R. Saidi, Tetrahedron, 2007, 63, 888–891 CrossRef CAS; (h) S. p. Azoulay, K. Manabe and S. Kobayashi, Org. Lett., 2005, 7, 4593–4595 CrossRef CAS PubMed; (i) K. Fagnou and M. Lautens, Org. Lett., 2000, 2, 2319–2321 CrossRef CAS PubMed.
  8. S.-M. Yang and W. V. Murray, Tetrahedron Lett., 2008, 49, 835–839 CrossRef CAS.
  9. (a) A. R. Kiasat and M. Fallah-Mehrjardi, Synth. Commun., 2010, 40, 1551–1558 CrossRef CAS; (b) A. R. Kiasat and M. F. Mehrjardi, Catal. Commun., 2008, 9, 1497–1500 CrossRef CAS.
  10. (a) A. R. Kiasat, S. Nazari and J. Davarpanah, C. R. Chim., 2014, 17, 124–130 CrossRef CAS; (b) A. R. Kiasat, N. Ayashi and M. Fallah-Mehrjardi, J. Iran. Chem. Soc., 2013, 10, 1175–1181 CrossRef CAS; (c) S. M. Baghbanian and M. Farhang, J. Iran. Chem. Soc., 2013, 10, 1033–1037 CrossRef CAS; (d) R. Munirathinam, D. Joe, J. Huskens and W. Verboom, J. Flow Chem., 2012, 2, 129–134 CrossRef CAS; (e) A. R. Kiasat and M. Fallah-Mehrjardi, J. Iran. Chem. Soc., 2009, 6, 542–546 CrossRef CAS; (f) A. R. Kiasat, R. Mirzajani, H. Shalbaf, T. Tabatabaei and M. Fallah-Mehrjardi, J. Chin. Chem. Soc., 2009, 56, 594–599 CrossRef CAS; (g) A. R. Kiasat, R. Badri, B. Zargar and S. Sayyahi, J. Org. Chem., 2008, 73, 8382–8385 CrossRef CAS PubMed; (h) S. E. Schaus, J. F. Larrow and E. N. Jacobsen, J. Org. Chem., 1997, 62, 4197–4199 CrossRef CAS.
  11. M. Boudou, C. Ogawa and S. Kobayashi, Adv. Synth. Catal., 2006, 348, 2585–2589 CrossRef CAS.
  12. (a) S. A. Taghavi, M. Moghadam, I. Mohammadpoor-Baltork, S. Tangestaninejad, V. Mirkhani, A. R. Khosropour and V. Ahmadi, Polyhedron, 2011, 30, 2244–2252 CrossRef CAS; (b) N. Iranpoor and B. Zeynizadeh, Synth. Commun., 1999, 29, 1017–1024 CrossRef CAS; (c) V. Mirkhani, S. Tangestaninejad, B. Yadollahi and L. Alipanah, Tetrahedron, 2003, 59, 8213–8218 CrossRef CAS.
  13. (a) A. R. Kiasat, N. Ayashi and M. Fallah-Mehrjardi, Helv. Chim. Acta, 2013, 96, 275–279 CrossRef; (b) N. Iranpoor and M. Shekarriz, Synth. Commun., 1999, 29, 2249–2254 CrossRef CAS.
  14. N. Azizi, E. Akbari, F. Ebrahimi and M. R. Saidi, Monatsh. Chem., 2010, 141, 323–326 CrossRef CAS.
  15. (a) N. Iranpoor, H. Firouzabadi and M. Shekarriz, Org Bioorg. Chem., 2003, 1, 724–727 RSC; (b) N. Iranpoor, T. Tarrian and Z. Movahedi, Synthesis, 1996, 12, 1473–1476 CrossRef.
  16. (a) K. Seth, S. R. Roy, D. N. Kommi, B. V. Pipaliya and A. K. Chakraborti, J. Mol. Catal. A: Chem., 2014, 392, 164–172 CrossRef CAS; (b) N. Azizi and M. R. Saidi, Catal. Commun., 2006, 7, 224–227 CrossRef CAS.
  17. V. Pace, P. Hoyos, M. Fernandez, J. V. Sinisterra and A. R. Alcantara, Green Chem., 2010, 12, 1380–1382 RSC.
  18. (a) D. W. Cho, P. S. Mariano and U. C. Yoon, Beilstein J. Org. Chem., 2014, 10, 514–527 CrossRef PubMed; (b) S. Coseri, Catal. Rev., 2009, 51, 218–292 CrossRef CAS.
  19. N. Barooah and J. B. Baruah, Mini-Rev. Org. Chem., 2007, 4, 292–309 CrossRef CAS.
  20. (a) J.-P. Sun, A. D. Hendsbee, A. F. Eftaiha, C. Macaulay, L. R. Rutledge, G. C. Welch and I. G. Hill, J. Mater. Chem. C, 2014, 2, 2612–2621 RSC; (b) P. B. Thale, P. N. Borase and G. S. Shankarling, RSC Adv, 2014, 4, 59454–59461 RSC; (c) H. Xin, X. Guo, F. S. Kim, G. Ren, M. D. Watson and S. A. Jenekhe, J. Mater. Chem., 2009, 19, 5303–5310 RSC.
  21. U. Sharma, P. Kumar, N. Kumar and B. Singh, Mini-Rev. Med. Chem., 2010, 10, 678–704 CrossRef CAS PubMed.
  22. N. A. Al-Masoudi, N. Al-Haidery, N. T. Failia and C. Pannecouque, ARKIVOC, 2010, 9, 185–195 Search PubMed.
  23. O. I. Aruoma and S. L. Cuppette, Antioxidant methodology; in vivo and in vitro concept, AOCS Press, Champaign, IL, USA, 1997, pp. 142–169 Search PubMed.
  24. M. Valko, D. Leibfritz and J. Moncol, Int. J. Biochem. Cell Biol., 2007, 39, 44–84 CrossRef CAS PubMed.
  25. H. Y. Zhang, D. P. Yang and G. Y. Tang, Drug Discovery Today, 2006, 11, 749–754 CrossRef CAS PubMed.
  26. L. Yu, J. Perret, B. Davy, J. Wilson and C. L. Melby, Food Chem. Toxicol., 2002, 67, 2600–2603 CAS.
  27. R. L. Prior, X. Wu and K. Schaich, J. Agric. Food Chem., 2005, 53, 4290–4302 CrossRef CAS PubMed.
  28. L. Sun, J. Zhang, X. Lu, L. Zhang and Y. Zhang, Food Chem. Toxicol., 2011, 49, 2689–2696 CrossRef CAS PubMed.
  29. M. Gul, I. Kulu, A. Peksel and N. Ocal, J. Chem., 2013 DOI:10.1155/2013/920130.
  30. (a) M. G. Dekamin and M. Eslami, Green Chem., 2014, 16, 4914–4921 RSC; (b) S. Zhang, Y.-N. Li, Y.-W. Zhang, L.-N. He, B. Yu, Q.-D. Song and X.-D. Lang, ChemSusChem, 2014, 7, 1484–1489 CrossRef CAS PubMed; (c) H. Kiyani and F. Ghorbani, Res. Chem. Intermed., 2014, 41, 4031–4046 CrossRef; (d) H. Kiyani and M. Ghiasi, Res. Chem. Intermed., 2014, 41, 5177–5203 CrossRef; (e) H. Kiyani and M. Ghiasi, Chin. Chem. Lett., 2014, 25, 313–316 CrossRef CAS; (f) H. Kiyani and F. Ghorbani, J. Saudi Chem. Soc., 2014, 18, 689–701 CrossRef; (g) M. G. Dekamin and Z. Karimi, J. Organomet. Chem., 2009, 694, 1789–1794 CrossRef CAS; (h) F. Matloubi Moghaddam, M. G. Dekamin and G. R. Kouzehgari, Lett. Org. Chem., 2005, 2, 734–738 CrossRef.
  31. (a) S. Ganesh Babu and R. Karvembu, Catal. Surv. Asia, 2013, 17, 156–176 CrossRef; (b) V. Polshettiwar, R. Luque, A. Fihri, H. Zhu, M. Bouhrara and J. M. Basset, Chem. Rev., 2011, 111, 3036–3075 CrossRef CAS PubMed; (c) S. Shylesh, V. Schunemann and W. R. Thiel, Angew. Chem., Int. Ed., 2010, 49, 3428–3459 CrossRef CAS PubMed.
  32. A. Kumar, R. Parella and S. A. Babu, Synlett, 2014, 25, 0835–0842 CrossRef CAS.
  33. (a) T. Azadbakht, M. A. Zolfigol, R. Azadbakht, V. Khakizadeh and D. Perrin, New J. Chem., 2015, 39, 439–444 RSC; (b) M. A. Zolfigol, T. Azadbkht, V. Khakizadeh, R. Nejatyami and D. Perrin, RSC. Adv, 2014, 4, 40036–40042 RSC; (c) M. A. Zolfigol, V. Khakyzadeh, A. R. Moosavi-Zare, A. Rostami, A. Zare, N. Iranpoor, M. H. Beyzavie and R. Luquef, Green Chem., 2013, 15, 2132–2140 RSC; (d) N. Koukabi, E. Kolvari, A. Khazaei, M. A. Zolfigol, B. Shirmardi-Shaghasemi and H. R. Khavasi, Chem. Commun., 2011, 47, 9230–9232 RSC.
  34. (a) M. A. Zolfigol, A. Khazaei, A. R. Moosavi-Zare, A. Zare and V. Khakyzadeh, Appl. Catal., A, 2011, 400, 70–81 CrossRef CAS; (b) M. A. Zolfigol, A. Khazaei, A. R. Moosavi-Zare, A. Zare, H. G. Kruger, Z. Asgari, V. Khakyzadeh and M. Kazem-Rostami, J. Org. Chem., 2012, 77, 3640–3645 CrossRef CAS PubMed; (c) A. R. Moosavi-Zare, M. A. Zolfigol, M. Zarei, A. Zare, V. Khakyzadeh and A. Hasaninejad, Appl. Catal., A, 2013, 467, 61–68 CrossRef CAS; (d) M. A. Zolfigol, H. Vahedi, S. Azimi and A. R. Moosavi-Zare, Synlett, 2013, 24, 1113–1116 CrossRef CAS; (e) A. R. Moosavi-Zare, M. A. Zolfigol, O. Khaledian, V. Khakyzadeh, M. D. Farahani and H. G. Kruger, New J. Chem., 2014, 38, 2342–2347 RSC; (f) A. R. Moosavi-Zare, M. A. Zolfigol and M. Daraei, Synlett, 2014, 25, 1173–1177 CrossRef; (g) A. R. Moosavi-Zare, M. A. Zolfigol, V. Khakyzadeh, C. Böttcher, M. H. Beyzavi, A. Zare, A. Hasaninejad and R. Luque, J. Mater. Chem. A, 2014, 2, 770–777 RSC; (h) M. A. Zolfigol, S. Baghery, A. R. Moosavi-Zare, S. M. Vahdat, H. Alinezhad and M. Norouzi, RSC. Adv, 2014, 4, 57662–57670 RSC; (i) M. A. Zolfigol, S. Baghery, A. R. Moosavi-Zare and S. M. Vahdat, RSC Adv, 2015, 5, 32933–32940 RSC; (j) M. A. Zolfigol, S. Baghery, A. R. Moosavi-Zare, S. M. Vahdat, H. Alinezhad and M. Norouzi, RSC Adv, 2015, 5, 45027 RSC; (k) M. Ghorbani, S. Noura, M. Oftadeh, E. gholamia and M. A. Zolfigol, RSC Adv., 2015, 5, 55303–55312 RSC; (l) A. R. Moosavi-Zare, M. A. Zolfigol, M. Zarei, A. Zare and V. Khakyzadeh, J. Mol. Liq., 2013, 186, 63–69 CrossRef CAS; (m) M. A. Zolfigol, A. R. Moosavi-Zare and M. Zarei, C. R. Chim., 2014, 17, 1264–1267 CrossRef CAS; (n) A. Khazaei, M. A. Zolfigol, A. R. Moosavi-Zare, J. Afsar, A. Zare, V. Khakyzadeh and M. H. Beyzavi, Chin. J. Catal., 2013, 34, 1936–1944 CrossRef CAS.
  35. (a) A. Zare, A. Hasaninejad, A. Khalafi-Nezhad, A. R. Moosavi-Zare, A. Parhami and G. R. Nejabat, ARKIVOC, 2007, 1, 58–69 Search PubMed; (b) G. H. Imanzadeh, A. Khalafi-Nezhad, A. Zare, A. Hasaninejad, A. R. Moosavi-Zare and A. Parhami, J. Iran. Chem. Soc., 2007, 4, 229–237 Search PubMed.
  36. (a) P. Salehi, M. M. Khodaie, M. A. Zolfigol and A. Keyvan, Synth. Commun., 2003, 33, 3041–3048 CrossRef CAS; (b) P. Salehi, M. Dabiri, M. A. Zolfigol and M. A. Bodaghi-Fard, Phosphorus, Sulfur Silicon Relat. Elem., 2004, 179, 1113–1121 CrossRef CAS.
  37. C. A. Rice-Evans, N. J. Miller and G. Paganga, Free Radical Biol. Med., 1996, 20, 933–956 CrossRef CAS PubMed.
  38. T. Azadbakht, M. A. Zolfigol, R. Azadbakht, V. Khakyzadeh and D. M. Perrin, New J. Chem., 2015, 39, 439–444 RSC.
  39. L. L. Mensor, F. S. Menezes, G. G. Leitao, A. S. Reis, T. S. Santos and C. S. Coube, Phytother. Res., 2001, 15, 127–130 CrossRef CAS PubMed.

Footnote

Electronic supplementary information (ESI) available. See DOI: 10.1039/c6ra07660b

This journal is © The Royal Society of Chemistry 2016
Click here to see how this site uses Cookies. View our privacy policy here.